- Main
Advancing Lentiviral Gene Therapy for Hemoglobinopathies: Lessons from Beta Globin Disorders and a Path Toward Alpha Thalassemia Correction
- Segura, Eva Eugenie Rose
- Advisor(s): Kohn, Donald Barry
Abstract
This work presents the efforts and achievements in developing safe and effective gene therapies for inherited hemoglobin disorders using lentiviral vector (LV) platforms in hematopoietic stem and progenitor cells (HSPCs). It highlights both the scientific evolution of the field and a novel therapeutic approach for alpha thalassemia major (ATM), an underserved and severe genetic condition.Chapter 1 presents a comprehensive review of the scientific journey that led to the first clinical successes in gene therapy for β-hemoglobinopathies. This chapter details key discoveries in the molecular regulation of the β-globin gene locus, the design and optimization of lentiviral vectors for high-level globin expression, and the translational research that enabled gene therapy to reach clinical application. The chapter also discusses how autologous hematopoietic stem cell transplant gene therapy (HSCT-GT) has emerged as a transformative alternative to allogeneic transplantation, particularly for patients lacking HLA-matched donors. It highlights major achievements including the FDA approval of Zynteglo™ , a curative autologous HSCT-GT, for transfusion-dependent β-thalassemia and provides a critical overview of the current clinical landscape for both β-thalassemia and sickle cell disease gene therapies. Chapter 2 describes the doctoral studies developed: an autologous HSCT-GT approach for alpha thalassemia, particularly ATM, using engineered lentiviral vectors to restore α-globin expression in patient-derived HSPCs. Unlike β-thalassemia, ATM currently lacks an approved gene therapy and is associated with severe anemia, hydrops fetalis, and lifelong transfusion dependence. In this work, a series of LVs were designed to express the human HBA2 gene under the regulation of a combination of optimized α-globin and/ or β-globin regulatory elements, such as the locus control region (LCR) element. The most promising constructs, EV-α and EV-α-UV, achieved 90–100% transduction efficiency, optimal range and distribution of vector copy numbers and safe integration patterns. When treated with candidate vectors, the α/β-globin mRNA and protein chain ratios from ATM-derived HSPCs from multiple donors reached therapeutic levels (0.5–0.8), and the hemoglobin levels improved by 50–100%, resulting in restoring red blood cell functionality. Additional analyses—including single-cell RNA sequencing, colony-forming unit assays, and engraftment measurements—demonstrated consistent transgene expression patterns, no vector-related toxicity, preservation of stemness and multilineage differentiation, and support for long-term engraftment potential. These results establish EV-α and EV-α-UV as clinically relevant vector candidates, reinforcing the feasibility of autologous HSCT-based gene therapy for ATM. Together, these chapters illustrate how foundational insights into globin gene regulation, vector engineering, and stem cell biology can converge to develop innovative treatments for both β- and α-globin disorders. This thesis bridges historical advancements in gene therapy with the generation of a novel therapeutic strategy poised to meet an unmet clinical need.